Core One Labs Highlights Key Points from International Investor Call



Ryan Allway

February 11th, 2021

Psychedelics


Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (“Core One”) is pleased with the tremendous turnout on the International Investors’ Call held earlier today. Core One’s Chairman, Dr. Robert E.W. Hancock and Chief Executive Officer, Joel Shacker provided participants an update on the Company’s current Intellectual Property and patent application process, cost to produce psilocybin, and the commercial viability.

Highlights

Intellectual Property and Patent Process

Dr. Hancock announced that the Company has assembled the necessary data for its research and development program on biosynthetic psilocybin production systems in order to commence the process of preparing and filing its first patent application with the United States Patent and Trademark Office. The initial filing is the first in a series of upcoming patent filings aimed at protecting valuable intellectual property that underpins the proprietary fermentative production process for active pharmaceutical ingredient (API) grade psilocybin.

Vocan Psilocybin Production Cost

Vocan’s process engineers bacteria incorporating optimized biosynthetic genes from the psilocybe cubensis mushroom which will enable the bacteria to act as a biological factory and synthesize psilocybin that is highly cost-effective using simple building blocks. The platform can make the active compounds that occur naturally by using a gene mimicry process and simple chemical modifications to enable the creation of bioidentical compounds, which can be proven to be more targeted and safer.

Comparison to Peers

Core One Lab’s has not identified any competitors that are currently developing biosynthesized psilocybin. There are other public companies producing psilocybin using different methods of production, such as synthetic psilocybin. Typical cost of synthesizing a form of pure psilocybin that meets standards set by the US Food and Drug Administration’s Good Manufacturing Practice is anywhere from $7,000 – $10,000 per gram.

In the current psilocybin environment, we have not identified any companies that are able to produce pure psilocybin at one hundredth of the current cost.

Speaking about other companies in the psilocybin space Dr. Robert E. W. Hancock, Chairman of the Company stated, “You might consider them competitors, but in our case, we consider them to be potential clients.”

“We are very happy to see such great attendance on today’s call. We are well positioned in psilocybin research and development of commercial products and look forward to providing future updates as they become available.” stated Joel Shacker CEO of the Company.

Shareholders and Investors are encouraged to visit our media section and view Dr. Robert E.W. Hancock’s insight into Vocan and Core One Labs.

Link: https://core1labs.com/media

About Core One Labs Inc.

Core One Labs Inc. is a research and technology company focused in life sciences and on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. The Company has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. With this technology, the Company intends to further develop its IP technology to focus on delivering psychedelic molecules with an initial focus on psilocybin. Core One also holds an interest in walk-in medical clinics which maintain a database of over 200,000 patients combined. Through research and development in these clinics, including the integration of its intellectual property related to psychedelic treatments and novel drug therapies, the Company intends to work towards regulatory approval for research that advances psychedelic-derived treatments for mental health disorders.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Latest posts